Juno Therapeutics (NASDAQ:JUNO) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.38 by 8 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Raymond James initiates coverage on Juno Therapeutics (NASDAQ:JUNO). The rating major has initiated the coverage with outperform rating on the shares. The rating by the firm was issued on June 2, 2016.
Juno Therapeutics (NASDAQ:JUNO): According to 8 Analysts, The short term target price has been estimated at $ 61.13.The target price could deviate by a maximum of $11.52 from the forecast price. In the near term, the target price could hit a high of $80 and a low of $ 50.
Juno Therapeutics (NASDAQ:JUNO) witnessed a decline in the market cap on Tuesday as its shares dropped 1.61% or 0.7 points. After the session commenced at $43.77, the stock reached the higher end at $43.9899 while it hit a low of $41.302. With the volume soaring to 1,420,252 shares, the last trade was called at $42.66. The company has a 52-week high of $59.6. The company has a market cap of $4,502 million and there are 105,535,597 shares in outstanding. The 52-week low of the share price is $22.37.
Shares of Juno Therapeutics Inc. rose by 3.9% in the last five trading days and 4.66% for the last 4 weeks. Juno Therapeutics Inc. is up 5.33% in the last 3-month period. Year-to-Date the stock performance stands at -2.98%.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.